Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, B. M.
Right arrow Articles by Kerr, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Greenberg, B. M.
Right arrow Articles by Kerr, D. A.
Related Collections
Right arrow Volumetric MRI
Right arrow All Immunology
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow All Spinal Cord
Right arrow Transverse myelitis
NEUROLOGY 2007;68:1614-1617
© 2007 American Academy of Neurology

Idiopathic transverse myelitis

Corticosteroids, plasma exchange, or cyclophosphamide

B. M. Greenberg, MD, MHS, K. P. Thomas, MD, C. Krishnan, MHS, A. I. Kaplin, MD, PhD, P. A. Calabresi, MD and D. A. Kerr, MD, PhD

From the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.

Address correspondence and reprint requests to Dr Greenberg, Department of Neurology, Johns Hopkins University School of Medicine 600 N. Wolfe St., Baltimore, MD 21287-5371 bgreenb7{at}jhmi.edu

Transverse myelitis is a focal disorder of the spinal cord in which an immune-mediated process results in neural injury. In this large retrospective study, we compare patients who received one of four treatments to identify the most effective therapies. We identified subsets of patients who received clinical benefit from plasma exchange or cyclophosphamide being included in their treatment regimen.

Supported by the Transverse Myelitis Association, Bruce and Deborah Downey, and the Katie Sandler TM Research Fund.

Disclosure: The authors report no conflicts of interest.

Received May 17, 2006. Accepted in final form February 27, 2007.




This article has been cited by other articles:


Home page
 Mult SclerHome page
M Bonnan, R Valentino, S Olindo, H Mehdaoui, D Smadja, and P Cabre
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder
Multiple Sclerosis, April 1, 2009; 15(4): 487 - 492.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Kumar, G. Sandhya, G. Rajshekher, R. Reddy, S. Prabhakar, B. M. Greenberg, and D. Kerr
IDIOPATHIC TRANSVERSE MYELITIS: CORTICOSTEROIDS, PLASMA EXCHANGE, OR CYCLOPHOSPHAMIDE
Neurology, January 8, 2008; 70(2): 160 - 160.
[Full Text] [PDF]

Home page
 JWatch NeurologyHome page
Which Treatment Is Best for Transverse Myelitis?
Journal Watch Neurology, July 3, 2007; 2007(703): 2 - 2.
[Full Text]

Correspondence:

Read all Correspondence

Idiopathic transverse myelitis: Corticosteroids, plasma exchange, or cyclophosphamide
Sudhir Kumar, et al.
Neurology Online, 30 Jul 2007 [Full text]
Reply from the authors
Benjamin M. Greenberg, et al.
Neurology Online, 30 Jul 2007 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.